Welcome to our dedicated page for XORTX Therapeutics news (Ticker: $XRTX), a resource for investors and traders seeking the latest updates and insights on XORTX Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XORTX Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XORTX Therapeutics's position in the market.
Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) has received a letter of compliance from Nasdaq regarding the minimum bid price requirement, leading to the curing of the deficiency. The company's common shares are now trading at or above US$1.00 per share for at least 10 consecutive trading days, resulting in the receipt of the compliance letter from Nasdaq. This development ensures that trading of the company's common shares on Nasdaq will continue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) announces the consolidation of its common shares on a 1:9 basis, with trading on the TSXV and Nasdaq to begin today. The consolidation is part of the Company's focus on developing therapies for progressive kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) announces the approval of consolidating its common shares on a one post-consolidation Share for every nine pre-consolidation Shares basis, effective November 9, 2023. The number of issued and outstanding Shares will be reduced from 17,989,687 to approximately 1,998,854. The Shares will continue to trade on the TSXV and the Nasdaq under the symbol XRTX on a post-Consolidation basis, under a new CUSIP number – 98420Q306.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
Rhea-AI Summary
XORTX Therapeutics Inc. announces new research findings on the role of uric acid in polycystic kidney disease and the potential of their proprietary formulation of oxypurinol as a treatment option. The studies show that moderate soluble uric acid can accelerate kidney expansion rate and worsen kidney function, and xanthine oxidase inhibition may be predictive of therapeutic benefit. The company plans to advance their formulation of oxypurinol in a clinical registration trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
-
Rhea-AI Summary
XORTX Therapeutics announces shareholder approval of share consolidation resolution to maintain NASDAQ listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
XORTX Therapeutics reschedules special meeting of shareholders to consider share consolidation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.81%
Tags
Rhea-AI Summary
XORTX Therapeutics cancels special meeting of shareholders and plans to reschedule. The meeting was called to consider a share consolidation to regain compliance with NASDAQ listing requirements. The cancellation is due to a significant change in shareholder base and potential misleading proxy solicitation activities. XORTX believes a NASDAQ listing is important for liquidity and funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.65%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. announces a special meeting of shareholders to consider a share consolidation for compliance with NASDAQ listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.4%
Tags
-
Rhea-AI Summary
XORTX Therapeutics announces acceptance of abstract on the effect of lowering uric acid on PKD in mice, to be presented at ASN meeting. Results suggest uric acid lowering is necessary for therapeutic benefit. Positive for XORTX's innovative therapies for kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
XORTX Therapeutics Inc. announces participation in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
XORTX Therapeutics Inc.
Nasdaq:XRTX
XRTX Rankings
XRTX Stock Data
7.25M
2.63M
4.08%
23.95%
0.73%
Support Activities for Nonmetallic Minerals (except Fuels) Mining
Mining, Quarrying, and Oil and Gas Extraction
United States of America
Calgary
About XRTX
xortx therapeutics inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. it has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. the company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. in addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. the company has a strategic alliance with teijin pharma limited to develop tmx-049, a xanthine oxidoreductase; and a partnership with the icahn school of medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with covid-19. xortx therapeutics inc. is headquartered in calgary, canada.